Morepen Laboratories Intrinsic Value
Morepen Laboratories (MOREPENLAB) median intrinsic value is ₹53.43 from 9 valuation models (range ₹16–₹135), vs current price ₹53.80 — -0.7% downside (Trading Near Calculated Value), margin of safety -0.7%. Read Morepen Laboratories dividend policy for the complete payout history and dividend yield track record.
MOREPENLAB Valuation Methods Summary — DCF, Graham Number & P/E
Morepen Laboratories intrinsic value across 9 models vs current price ₹53.80 — upside/downside and value range per method. Analyse MOREPENLAB shareholding pattern to track promoter, FII and institutional holdings.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹24.64 | ₹19.71 - ₹29.57 | -54.2% | EPS: ₹1.12, Sector P/E: 22x |
| Book Value Method | asset | ₹134.50 | ₹121.05 - ₹147.95 | +150.0% | Book Value/Share: ₹113.27, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹107.60 | ₹96.84 - ₹118.36 | +100.0% | Revenue/Share: ₹179.27, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹107.60 | ₹96.84 - ₹118.36 | +100.0% | EBITDA: ₹132.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹27.01 | ₹21.61 - ₹32.41 | -49.8% | CF Growth: 5.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹16.14 | ₹14.53 - ₹17.75 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹17.30 | ₹15.57 - ₹19.03 | -67.8% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹58.18 | ₹52.36 - ₹64.00 | +8.1% | ROE: 5.1%, P/E Multiple: 10x |
| Graham Defensive Method | conservative | ₹53.43 | ₹48.09 - ₹58.77 | -0.7% | EPS: ₹1.12, BVPS: ₹113.27 |
MOREPENLAB Intrinsic Value vs Market Price — All Valuation Models
Morepen Laboratories fair value range ₹16–₹135 vs current market price ₹53.80 across 9 valuation models. For current market price and key ratios, visit Morepen Laboratories share price screener.
MOREPENLAB Intrinsic Value Analysis — Undervalued or Overvalued?
Morepen Laboratories median intrinsic value ₹53.43, current price ₹53.80 — Trading Near Calculated Value by 0.7%, margin of safety -0.7%.
What is the intrinsic value of MOREPENLAB?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Morepen Laboratories (MOREPENLAB) is ₹53.43 (median value). With the current market price of ₹53.80, this represents a -0.7% variance from our estimated fair value.
The valuation range spans from ₹16.14 to ₹134.50, indicating ₹16.14 - ₹134.50.
Is MOREPENLAB undervalued or overvalued?
Based on our multi-method analysis, Morepen Laboratories (MOREPENLAB) appears to be trading near calculated value by approximately 0.7%.
MOREPENLAB Financial Health — Key Ratios vs Industry Benchmarks
Morepen Laboratories financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 5.85 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 5.1% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | 5.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 1.02x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
MOREPENLAB Cash Flow Quality — Operating & Free Cash Flow
Morepen Laboratories operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹32 Cr | ₹-129 Cr | Positive Operating Cash Flow | 6/10 |
| March 2024 | ₹73 Cr | ₹32 Cr | Positive Free Cash Flow | 7/10 |
| March 2023 | ₹-91 Cr | ₹-115 Cr | Negative Cash Flow | 3/10 |
| March 2022 | ₹-60 Cr | ₹-76 Cr | Negative Cash Flow | 3/10 |
| March 2021 | ₹51 Cr | ₹16 Cr | Positive Free Cash Flow | 7/10 |